Dyspareunia Clinical Trials 2023

What are the top hospitals conducting dyspareunia research?

Dyspareunia, a condition characterized by painful sexual intercourse, is receiving attention and research at various locations across the United States. In sunny Sarasota, Site 117 has taken an active role in exploring new treatment options with their ongoing clinical trial dedicated to dyspareunia. This trailblazing hospital recorded its first dyspareunia trial in 2022, paving the way for potential breakthroughs in understanding and managing this often misunderstood condition. Similarly committed to tackling dyspareunia, Site 113 in Norcross is conducting their own active clinical trial on this topic. With a shared focus on advancing knowledge and improving patient outcomes, these hospitals demonstrate a dedication to addressing the challenges faced by individuals affected by dyspareunia.

Meanwhile, at Site 104 situated in Wichita as well as Site 10112 located in Birmingham have also joined the quest for solutions through their respective active trials for dyspareunia. By initiating investigations into effective interventions and therapies, they strive to alleviate the burden of pain experienced during sexual activities for those who suffer from this condition.

In picturesque Sacramento resides another institution fueling progress against dyspareunia - Site 10103. Their commitment shines through an ongoing clinical trial tailored specifically towards finding relief from painful intercourse. All five of these hospitals are united not only by their current endeavors but also by their shared accomplishments—each having completed one previous dyspareunia clinical trial since recording their inaugural investigation just last year.

The efforts undertaken by these hospitals signify a step forward towards better understanding and management of this distressing condition that affects countless individuals worldwide. Through diligent research and collaborative approaches within medical communities across different regions throughout America proper attention can be given ensuring brighter futures for patients facing difficulties due to Dysprarenuas

Which are the best cities for dyspareunia clinical trials?

When it comes to dyspareunia clinical trials, several cities show promise in advancing research and treatment options. Washington, D.C., stands out with three active trials exploring innovative interventions like transvaginal photobiomodulation. Norcross, Georgia; Wichita, Kansas; Sacramento, California; and Miami Lakes, Florida all have two ongoing studies focused on evaluating the efficacy of estradiol vaginal inserts at a dosage of 4 mcg and other potential treatments for dyspareunia. These cities provide individuals suffering from this condition with opportunities to participate in cutting-edge clinical trials that may lead to improved outcomes and enhanced quality of life.

Which are the top treatments for dyspareunia being explored in clinical trials?

Exciting progress is being made in the realm of dyspareunia treatment, as clinical trials explore various potential solutions. Noteworthy contenders include:

• Transvaginal photobiomodulation: Currently undergoing one active trial and boasting the distinction of being the first listed option dedicated to dyspareunia in 2023.
• Estradiol: Showing promise with one ongoing trial and a total of three all-time dyspareunia trials since its introduction in 2013.
• Vaginal moisturizer: Garnering attention with one active trial, this novel approach has quickly emerged on the scene after its first listing in 2022.
• 4% Topical Lidocaine Gel: Making waves as an alternative therapy for dyspareunia, this gel is currently involved in one active trial following its introduction to clinical research back in 2018.

The exploration of these treatments brings hope for individuals seeking relief from dyspareunia, pushing us closer to finding effective solutions for their needs.

What are the most recent clinical trials for dyspareunia?

Promising advancements in the field of dyspareunia are emerging through recent clinical trials. One such trial focuses on the use of estradiol, a hormone that has shown potential in addressing this condition. With Phase 4 results now available as of September 1, 2023, researchers and patients alike eagerly anticipate further insights into its effectiveness. Additionally, another trial investigated the benefits of estradiol vaginal inserts containing 4 mcg for dyspareunia. This Phase 3 study became available on November 15, 2022, offering hope for individuals seeking relief from this distressing condition. These exciting developments highlight ongoing efforts to understand and mitigate dyspareunia's impact on patients' lives.

What dyspareunia clinical trials were recently completed?

Recently completed clinical trials in the field of dyspareunia, a condition characterized by painful intercourse, have made significant strides towards improving treatment options. These trials shed light on potential interventions to alleviate this distressing symptom. Stay tuned for updates on the latest research findings and their implications for individuals grappling with dyspareunia.